Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences:

• Piper Sandler 37^th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NY
• Evercore 8^th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gables, FL

Live webcasts of each fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC^® gene targeted chimera small molecules. The company’s GeneTAC^® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC^® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing DT-818 for myotonic dystrophy type-1, and a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:
Renee Leck
THRUST Strategic Communications
[email protected]

You May Also Be Interested In

• Invest In the USA (IIUSA) Submits Comprehensive Comments on DHS EB-5 Notice of Proposed Rulemaking
• PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual Meeting
• HWH International Inc. Announces Executive Leadership Transition